Cytokinetics Reports Strong Q3 2026 Revenue Growth Driven by MYQORZO Adoption
Cytokinetics (CYTK) reported significant growth in its third quarter of 2026, with total revenues reaching $47.6 million, a massive increase from $1.9 million in the same period last year. This surge was primarily driven by net product revenue of $44.5 million, representing 76% growth over the previous quarter as demand for its cardiac myosin inhibitor, MYQORZO, continues to scale among U.S. cardiovascular healthcare providers. The company's commercial footprint is expanding rapidly, with unique U.S. prescribers increasing from 700 to 1,100 and patient volume rising 86% since the end of Q2. Despite higher selling, general, and administrative expenses due to launch costs, Cytokinetics narrowed its net loss to $190.1 million compared to a much larger loss in the prior year. The company maintains a strong liquidity position with $1.6 billion in cash and investments.
Tickers: $CYTK
Topics: cardiovascular healthcare earnings report product adoption revenue growth